Elevidys market report flags faster growth in gene therapy demand

The Business Research Company says the Elevidys market is drawing stronger interest as gene therapy advances reshape treatment prospects for Duchenne muscular dystrophy. The report points to North America as the largest regional market in 2025 and says Asia-Pacific is set for the fastest growth through 2035.

Why it matters: - Elevidys sits in a growing market tied to Duchenne muscular dystrophy, a rare genetic disease with no curative standard treatment. - Rising diagnosis rates and expanding gene therapy adoption could increase demand for targeted therapies that address the underlying cause of the disease. - The report frames Elevidys as part of a broader shift toward curative approaches in neuromuscular care.

What happened: - The Business Research Company released its Elevidys Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report says Elevidys is a prescription gene therapy developed by Sarepta Therapeutics for Duchenne muscular dystrophy. - The therapy delivers a shortened but functional version of the dystrophin gene, called micro-dystrophin, to help restore dystrophin protein function. - The report is available as a free sample here. - The full report is available here.

The details: - Historical market growth has been supported by the lack of curative treatments for DMD, reliance on supportive care, early gene therapy research, rare disease drug incentives and initial regulatory approvals. - Future growth is expected to be driven by gene editing breakthroughs, more funding for neuromuscular disorder studies, wider newborn screening, more specialized treatment centers and supportive regulatory frameworks. - Current market trends include broader use of gene therapies, stronger focus on curative treatments, more targeted DMD therapies, earlier intervention and better viral vector delivery systems. - The report says increasing DMD prevalence is a key market driver. - DMD is caused by mutations in the dystrophin gene and leads to the absence of dystrophin protein, which causes progressive muscle weakening and degeneration. - Improved awareness and diagnostic methods are helping detect the disease earlier and more often, increasing demand for treatment. - In December 2023, the Murdoch Children’s Research Institute in Australia reported that about 1,000 people in Australia live with Duchenne muscular dystrophy. - North America held the largest share of the Elevidys market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and future trend analysis.

Between the lines: - The report suggests Elevidys is benefiting from a broader commercialization wave around rare-disease gene therapies. - Regional growth patterns point to a mature U.S.-led market today, with faster expansion likely in Asia-Pacific as screening and treatment infrastructure improve. - The added analytics in the 2026 report signal that investors and drugmakers are looking for more detailed competitive intelligence, not just market sizing.

What's next: - The report expects continued growth as newborn screening expands and more patients are identified earlier. - Adoption will likely hinge on how quickly gene editing, delivery systems and specialized treatment networks mature. - The Business Research Company says its expanded strategic intelligence tools are now part of the 2026 market report series.